Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni
129  

Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni

Gilead Sciences, Inc. announced plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will ...

September 25, 2018
News  
GNP+ Announces Search for Executive Director
304  

GNP+ Announces Search for Executive Director

The Global Network of People Living with HIV (GNP+) is searching for a skilled and passionate leader and manager to lead its organization in the implementation of an exciting and ambitious strategic plan.

September 18, 2018
News  
Global Fund Partnership has Saved 27 Million Lives
252  

Global Fund Partnership has Saved 27 Million Lives

The Global Fund to Fight AIDS, Tuberculosis and Malaria released a report today demonstrating that 27 million lives have been saved by the Global Fund partnership. The report shows tremendous progress that has been achieved by efforts to end the epidemics, while highlighting new threats.

September 14, 2018
News  
Studies show dolutegravir monotherapy is an unsafe switch option
289  

Studies show dolutegravir monotherapy is an unsafe switch option

Using dolutegravir alone, as maintenance treatment after achieving undetectable viral load on a three-drug regimen, results in an unacceptable rate of viral rebound and is unethical in the view of many experts, the 22nd International AIDS Conference (AIDS 2018) heard last month.

August 19, 2018
News